NCT00849667

Who might be able to join this trial:

• You have been diagnosed with a specific type of ovarian cancer (non-mucinous epithelial ovarian cancer), or a related cancer starting in the peritoneum or fallopian tubes, confirmed by a lab test
• Your cancer can be measured on a CT or MRI scan
• Your cancer has come back between 6 and 24 months after finishing your first course of platinum-based chemotherapy
• You have previously had surgery to remove as much of the tumour as possible, followed by chemotherapy using platinum and taxane drugs
• You may have previously received bevacizumab as a maintenance treatment, as long as your last dose was at least 30 days before the study starts (no other maintenance chemotherapy or cancer vaccine treatments are allowed)
• You are considered suitable to receive carboplatin and taxane chemotherapy again
• You have little or no nerve damage (such as numbness or weakness) from previous treatment (confirm with trial site)

Who may not be able to join:

• Your cancer did not respond to your first platinum-based chemotherapy, or it came back either less than 6 months or more than 24 months after finishing it
• You have already received any treatment for your cancer since it came back
• The cancer has spread to your brain or central nervous system
• You have had another active serious cancer that required treatment within the last 5 years
• You have had a known allergic reaction to a monoclonal antibody treatment before, or have developed certain antibodies against such treatments (confirm with trial site)
• You have previously been treated with a drug called MORAb-003 (farletuzumab)
• There is a medical reason why you cannot safely receive taxane chemotherapy

Important: Always verify eligibility with the trial site directly before applying.